Real-World data reveals impact of MS drug on disability progression
NCT ID NCT07168694
Summary
This study looked back at the medical records of 606 people in Russia with secondary progressive multiple sclerosis (SPMS) who were treated with the drug siponimod. The goal was to understand the real-world effects of this treatment on disability progression and relapse rates. Researchers analyzed data from 11 MS centers to see how patients fared over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.